The clinical course of neuroblastoma stage 4S or MS is characterized by a high rate of spontaneous tumor regression and favorable outcome. However, the clinical course and rate of the regression are poorly understood.
INTRODUCTION
Neuroblastoma stage 4S (S for "Special") defined patients < 12 months old with primary tumors stage 1 or 2 and dissemination limited to specific sites, such as liver, bone marrow (< 10% invasion), and skin. 1 In the International Neuroblastoma Risk Group Staging System (INRGSS), the age limit was extended to 18 months, and primary tumor stage was not taken into account anymore. 2 In all staging systems, osteomedullary tracer uptake on 99 Tc bone scans or 123 I-MIBG scans defines stage 4. Stage 4S is characterized by a favorable course of disease and a high rate of spontaneous tumor regression. [1] [2] [3] Long-term survival rates are estimated between 65% and 92%. [4] [5] [6] [7] In general, neuroblastoma 4S can be managed by active surveillance in expectation of spontaneous tumor regression. In patients with symptoms of organ compression, antitumor treatment (chemotherapy or low-dose radiotherapy to the liver) is advised. Although the tumor regresses in most patients, very young patients are at risk of early and rapid progression of liver metastases, causing life-threatening compression of lungs, kidneys, inferior vena cava, normal liver tissue, and intestines. 8 Tumor progression to true stage 4 or high-risk disease is seen occasionally.
This can occur before complete regression and is different from lateonset recurrent disease.
Previously, we explained regression as a process of delayed differentiation of tumor nodules. 9 We consider stage 4S as a multifocal developmental disease with an onset in the early stage of neural crest development. (Pre)migratory neural crest cells suffer from a defect and spread to different target organs of the neural crest (skin, liver, bone marrow, adrenal glands, sympathetic side chain) to form proliferative tumor nodules. The tumor regression reflects a delayed step of cellular differentiation and apoptosis. 9 The process and clinical regression rate have not been studied for the expected time to normalization on different modalities. Also, it is not clear if antitumor treatment (chemotherapy and radiotherapy) has any effect on the initiation of the regression process.
Here, we studied the survival rates, frequency, and rate of tumor regression in a retrospective cohort of patients with neuroblastoma stage 4S. We describe risk factors of progressive disease. Finally, we evaluated the effect of therapy on disease regression. 
METHODS

Patient cohort
Radiological evaluation
All radiological and nuclear scan reports were reviewed (MT and BdK).
For the liver, both size and architecture were evaluated. Liver size was compared with age-related reference levels. 11 Patients with an event (progression and death) were excluded from the long-term regression analysis.
Metabolic evaluation
Urinary homovanillic acid (HVA) and vanillylmandelic acid (VMA) were measured and reported (fold change of the upper limit for age; defined as mean +2 SD) as described previously. 12 Time from diagnosis to last abnormal value was used instead of time to normalization. This probably represented a more accurate time to normalization because the lack of standardized intervals occasionally resulted in long periods between last abnormal (but slightly elevated values) and first normal values. Additionally, a few patients maintained elevated HVA (n = 4) or VMA (n = 3) excretion levels even after years of follow-up. By using time to first normal measurement, we would have to exclude these patients, causing information bias. were considered statistically significant.
Statistical analysis
RESULTS
Patient characteristics
We identified 35 patients with the clinical diagnosis of neuroblastoma stage 4S, representing 8% of total neuroblastoma diagnoses. After exclusion of patients with MYCN amplification (n = 4), 31 patients were included (Supporting Information Table S1 ). The median age at diagnosis was 70 days (range, 1-228 days). Seven (23%) patients were < 4 weeks old. The primary tumor was located in the adrenal gland in 23 (74%) (five patients had bilateral adrenal tumors), in the sympathetic side chain in 5 (16%) patients, and remained unknown in 3 (10%) patients. All patients except one had liver metastases, and 5 (16%) had skin metastases. Bone marrow was evaluated in 28 patients and infiltrated in 7 (25%) ( Table 1) . Antitumor treatment was given in 16 (52%) patients: 12 (39%) patients received chemotherapy, 7 (23%) received Iodine-131-Metaiodobenzylguanidine ( 131 I-MIBG) therapy, 6 (19%) received radiotherapy, and the primary tumor was surgically removed in 5 (16%) patients (Supporting Information Table   S1 ). One patient was presented in a case report previously. 13 
Survival and response
The 10-year OS and EFS rates were 84% ± 7% and 69% ± 9% ( Figure 1A ), respectively. At last follow-up, 18 (58%) patients had reached complete remission (CR), 8 (26%) (very good) partial remission ((VG)PR), and 5 (16%) had died of neuroblastoma. This was similar in treated and untreated patients ( Table 1 ). 
Tumor regression
Liver
Regression of liver metastases was studied in 23 of 30 patients with 
Metabolic regression
Regression of the catecholamines HVA and VMA was studied in 24 of 31 patients. In the other seven patients, excretion levels were not available because of rapid progression (n = 4) or before this was standard of care (n = 3). HVA levels normalized in 20 (83%) patients and VMA in 21 (88%) patients. Last abnormal values were measured after a median of 2.2 months for HVA (range, 0-158) and 1.6 months for VMA (range, 0-158) ( Figure 2 ), which was comparable between treated and untreated patients (P = 0.32 and P = 0.14, respectively) ( Table 1 ).
Progressive disease
Patients with progressive disease were subcategorized in three types of progression. Four patients died of fast initial tumor progression died within two days after admission. The two older patients, 6 weeks and 6 months old, survived. In total, four of seven patients < 4 weeks old (58%) died of type A progression, resulting in a significant higher risk of dying due to type A progression for younger than for older patients ( Figure 1C ; log-rank P < 0.001).
Type A progression: fast initial tumor progression with increase of the liver mass
Type B progression: progression to stage 4 disease < 5 years from diagnosis
Type B progression occurred in three patients-3, 8, and 13 months after initial diagnosis-and was fatal in one patient despite high-risk treatment ( Table 1 ). The remaining two patients are in CR, 99 and 108 months after progression. In none of the patients with type B progression, catecholamine excretion normalized prior to the progression. In contrast, patients with no progression and finally CR, catecholamines normalized after 1.2 months (range, 0-8.9 months) for HVA and 0.7 months (range, 0-4.2 months) for VMA ( Figure 3 ; type B progression vs CR: P = 0.02 for HVA, P < 0.01 for VMA). 
Type C progression: late recurrent disease after > 5 years
Copy-number analysis
Twenty tumors were evaluated for numerical chromosomal aberrations (NCA; whole chromosome gains and losses) and for segmental chromosomal aberrations (SCA; partial gains and losses). 14 Table S2 ). The patient with type C stage 4 progression had both NCA and SCA at the time of 4S diagnosis. In this limited cohort, significant differences were observed in EFS when patients were classified in the different genomic pattern groups. Patients with only NCA had a 10-year EFS of 89% ± 11%, patients with both NCA and SCA had a 10-year EFS of 86% ± 13%, and patients with only SCA had a significantly poorer 10-year EFS 0% (log-rank P < 0.01; Supporting Information Figure S1 ).
DISCUSSION
We performed a retrospective cohort study investigating the regression kinetics and risk factors of progression in patients with stage 4S neuroblastoma. In this cohort of 31 patients, the 10-year OS was 84% ± 7%. Catecholamine excretion and liver size normalization occurred in 83% and 91% of the patients after a median of two in 42% and 48% of 28 and 15 patients, respectively. 15, 16 One study described liver size normalization in < 12 months in two patients. 17 Early expansion of liver metastases caused respiratory distress requir- Antitumor treatment is given in patients with type A progression in an attempt to induce tumor regression to prevent clinical complications of organ compression. However, its effectiveness has never been proven. Here, the commonly used combination of vincristine and cyclophosphamide did not result in arresting the progression in the two treated young patients. Additionally, we observed no difference in the outcome or the regression rate of patients with or without treatment. Although this is a retrospective study with a limited number of patients, which hampers a proper analysis of baseline differences in tumor load, the question is raised whether antitumor therapy influences the outcome or regression in very young children with this type of early progression, and if antitumor treatment is needed in older stage 4S patients. Moreover, a recent large prospective study could not establish an effect of chemotherapy on tumor regression or outcome. 22 Considering the concept of delayed differentiation of early neural crest cells and subsequent differentiation, 9 the question is valid if chemotherapy can accelerate the differentiation and regression process or if it can halt the progression. Therefore, it would be best to study (early) response kinetics in detail in a prospective cohort.
The retrospective design and the long inclusion period are obvious limitations of the study. In this 40-year period, improvements have been achieved in the quality and availability of imaging techniques and other diagnostics. Supportive care and treatment protocols have also been improved; our current treatment protocol contains doxorubicin in addition to cyclophosphamide and vincristine. Still, one of the patients who died of type A progression was diagnosed in 2011, when all modern imaging modalities were present and our current treatment protocol was standard care.
All patients with type B progression to stage 4 disease retained elevated catecholamine excretion until tumor progression was observed, suggesting that these tumors are biologically different from tumors that regress. A different biology is also suggested by the higher number of patients with structural chromosomal aberrations. 23 This is consistent with earlier reports that tumors with segmental aberrations have a more aggressive disease. 14, 23, 24 Because CNA was tested in only a small number of patients in this study, we cannot draw definitive conclusions. However, in the ongoing European LINES trial, the effect of the CNA in this group is being prospectively studied. Recent research concluded that the combination of telomere maintenance activity and aberrations in the RAS and TP53 pathways can predict unfavorable outcome in low-risk patients. 25 It would be interesting to see if these parameters are helpful in making treatment decisions.
In conclusion, patients with neuroblastoma stage 4S have a favorable outcome as a result of spontaneous tumor regression. Biochemical regression precedes radiological normalization and is usually reached within the first months. Children < 2 months old at diagnosis are at risk of fatal outcome in the first weeks after diagnosis due to tumor progression and it is strongly recommended to watch them closely and consider treatment. The remainder of patients has a small chance to progress to high-risk disease, especially when they have normalized biochemical activity and no segmental gains and losses in their tumor genome.
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